The content on this page is designed for . Check courses designed for Canada (EN)

This course has expired. View available courses.

Respirology

New Avenues for Promoting Control in Chronic Disease: Opportunities in Asthma, COPD, and Diabetes – Ordre des pharmaciens du Québec (OPQ)

Upon completion of this program, participants will be able to:

Asthma Module

  1. Assess current asthma control.
  2. Make recommendations to adjust therapy for optimal current and future control of asthma.
  3. Counsel patients about the importance of adhering to therapy to promote future control and prevent exacerbations.

COPD Module

  1. Make recommendations to optimize management of COPD using current approaches.
  2. Make recommendations to help patients with COPD prevent future acute exacerbations.
  3. Counsel patients about medication adherence using the written action plan, for promotion of disease control.

Diabetes Module

  1. Describe the role of the new class of SGLT2i agents in the management of type 2 diabetes for health-promotion.
  2. Identify patients for whom SGLT2i therapy is appropriate, based on patient and agent characteristics.
  3. Counsel patients to support adherence, safety, and efficacy when initiating an SGLT2i.

DURATION

PROFESSION

# OF CREDITS

1.50

ACCREDITATION

EXPIRY DATE

1969-12-31

Upon completion of this program, participants will be able to:

Asthma Module

  1. Assess current asthma control.
  2. Make recommendations to adjust therapy for optimal current and future control of asthma.
  3. Counsel patients about the importance of adhering to therapy to promote future control and prevent exacerbations.

COPD Module

  1. Make recommendations to optimize management of COPD using current approaches.
  2. Make recommendations to help patients with COPD prevent future acute exacerbations.
  3. Counsel patients about medication adherence using the written action plan, for promotion of disease control.

Diabetes Module

  1. Describe the role of the new class of SGLT2i agents in the management of type 2 diabetes for health-promotion.
  2. Identify patients for whom SGLT2i therapy is appropriate, based on patient and agent characteristics.
  3. Counsel patients to support adherence, safety, and efficacy when initiating an SGLT2i.
Cost of course:  
Free
# of credits: 1.50
Duration:

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.

New Avenues for Promoting Control in Chronic Disease: Opportunities in Asthma, COPD, and Diabetes – Ordre des pharmaciens du Québec (OPQ)

Duration

Profession

1.50

# of credits

Learning Objectives

ACF Learning Objectives

ACCREDITATION

Respirology

Learning Category

General

Topic

0

Price

1969-12-31

Expiry Date

Region/Language

Course Description

Upon completion of this program, participants will be able to:

Asthma Module

  1. Assess current asthma control.
  2. Make recommendations to adjust therapy for optimal current and future control of asthma.
  3. Counsel patients about the importance of adhering to therapy to promote future control and prevent exacerbations.

COPD Module

  1. Make recommendations to optimize management of COPD using current approaches.
  2. Make recommendations to help patients with COPD prevent future acute exacerbations.
  3. Counsel patients about medication adherence using the written action plan, for promotion of disease control.

Diabetes Module

  1. Describe the role of the new class of SGLT2i agents in the management of type 2 diabetes for health-promotion.
  2. Identify patients for whom SGLT2i therapy is appropriate, based on patient and agent characteristics.
  3. Counsel patients to support adherence, safety, and efficacy when initiating an SGLT2i.

Faculty

ACF Faculty

Accreditation

Unaccredited